Clinical trial · Observational
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Collaboration on Neuroimmunology: Question, Understand, Educate, Restore - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuromyelitis Optica | — | UNRESOLVED | — |
| Neuromyelitis Optica Spectrum Disorder | — | UNRESOLVED | — |
| Optic Neuritis | — | UNRESOLVED | — |
| Transverse Myelitis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (4)
- label
- Neuromyelitis Optica Spectrum Disorder
- description
- Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
- label
- Transverse Myelitis and Optic Neuritis
- description
- Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
- label
- Healthy Controls
- description
- patients without a history of CNS inflammation
- label
- Neuromyelitis Optica
- description
- patients diagnosed with NMO
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
Show eligibility criteria text
Inclusion Criteria: * Age 6 years or greater * Male or Female * Patient or Parent (in the case of a minor) able to give informed consent * For patients 10 to 17, patient able to assent * Patient diagnosed with NMO, NMOSD, TM or ON Exclusion Criteria: * Unable to maintain scheduled visits * Patient has known HIV or hepatitis C infection
References
Publications (0)
Data not yet available